uniQure N.V. (NASDAQ:QURE), a biotechnology company known for its focus on gene therapy, is set to release its quarterly earnings on March 2, 2026. Wall Street anticipates a loss of $0.93 per share, with projected revenue of approximately $4.7 million. Despite these expectations, uniQure faces significant legal challenges that could impact its financial performance.
uniQure is currently embroiled in a class action lawsuit for alleged violations of securities laws. The lawsuit, filed by the DJS Law Group, claims that the company made false and misleading statements regarding its Pivotal Study design and its comparison to the ENROLL-HD data set. These issues reportedly contributed to delays in securing full FDA approval for its Biologics License Application (BLA).
The legal challenges are compounded by uniQure's financial metrics, which indicate ongoing struggles. The company has a negative price-to-earnings (P/E) ratio of -4.26, reflecting its lack of profitability. Additionally, its price-to-sales ratio is 66.94, suggesting that investors are paying a high premium for each dollar of sales. This is further supported by an enterprise value to sales ratio of 33.23.
Despite these financial hurdles, uniQure maintains a relatively low debt-to-equity ratio of 0.29, indicating conservative debt usage. The company's current ratio of 7.12 suggests strong liquidity, meaning it can cover its short-term liabilities. However, the negative enterprise value to operating cash flow ratio of -3.42 and an earnings yield of -23.48% highlight ongoing financial challenges.
The legal actions against uniQure are not isolated, as the Schall Law Firm and Rosen Law Firm have also announced class action lawsuits. These lawsuits target investors who purchased QURE shares between September 24, 2025, and October 31, 2025. Affected shareholders are encouraged to contact these firms before the April 13, 2026 deadline to discuss their rights and potential participation in the lawsuits.
